AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 172 min read$BIAF

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant - bioAffinity Technologies (NASDAQ

BioAffinity Technologies (NASDAQ:BIAF) shares rose 50.47% to $8.05 Thursday after receiving a Hong Kong patent for its CyPath Lung diagnostic. The patent complements a 2025 patent in China, covering a region with high lung cancer incidence. CyPath Lung has shown strong clinical performance, with 92% sensitivity and 87% specificity in trials. The company's warrants (NASDAQ:BIAFW) also gained nearly 20%.

Original reporting
benzinga.com
Published Sep 17, 2026, 7:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 7:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$BIAF
Bullish
high confidence
Mentioned
$BIAF
Relevance
7/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$BIAFBullishMed
01

Why it matters

The dual‑region IP coverage is expected to solidify market positioning and could translate into higher sales and partnership opportunities.

02

Market read

The patent grant is a catalyst for a sharp price increase and may influence investor sentiment toward similar biotech firms.

03

What to watch

Potential competition from other liquid‑biopsy platforms and regulatory hurdles in other jurisdictions.

Relevance 7/10Novelty 8/10Timing: Thursday afternoon

Background

BioAffinity Technologies (NASDAQ:BIAF) develops non‑invasive lung cancer diagnostics. The company recently secured a Chinese patent and now adds Hong Kong protection.

Company-level read

Ticker impact

$BIAFBullishHigh confidence
Context

BioAffinity Technologies shares jumped 50% after the Hong Kong patent for its CyPath Lung diagnostic was granted, a fresh catalyst driving the surge.

Expected impact

upward pressure as investors buy on the news

Evidence & confidence

New, material IP protection in a key region directly triggers a large intraday price move; similar biotech patent approvals have historically led to sustained upside.

Market effects

Sector

Strengthens the lung‑diagnostics niche and may boost related biotech peers with similar IP strategies.

Regional

Highlights Hong Kong/China as a growing market for advanced diagnostics, potentially attracting investor interest in Asian biotech listings.

Global

Adds to the narrative of expanding non‑invasive cancer diagnostics worldwide.

Counterpoint

What could challenge this read

The rally may be over‑optimistic if commercialization timelines or reimbursement approvals lag behind the patent grant.

Key entities

  • company
    BioAffinity Technologies Inc.

    Developer of the CyPath Lung diagnostic platform.

Read at source← All news

Related articles

SEP 5
$BIAFMedAI 8/10

bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right?

bioAffinity Technologies (BIAF) rose 47.95% after announcing its AI-based lung-cancer surveillance tool, CyPath Lung, and a 1-for-15 reverse stock split. Q2 test volume surged 216% YoY, but the company reported a $3.4M net loss and $2.4M cash. Clinical study results showed 92% sensitivity and 88% accuracy. The company faces challenges in scaling revenue and managing dilution risks.

insidermonkey.com3 min
SEP 3
$BIAFHigh

Why is bioAffinity Technologies stock surging today?

bioAffinity Technologies (BIAF) stock surged 39.4% in pre-market trading after announcing its CyPath® Lung test can now monitor lung cancer recurrence, expanding its commercial use. The company's small float, due to a recent reverse stock split, amplified the price movement. The broader market showed no significant impact.

investing.com2 min
SEP 2
$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

rttnews.com2 min
AUG 7
$BIAFMed

bioAffinity Technologies, Inc. (BIAF): Results of Operations and Financial Condition

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and advances longitudinal clinical

SEC EDGAR 8-K6 min
SEP 17
$XENEMed

Xenon Pharma stock tumbles on psychiatry trial pause

Xenon Pharmaceuticals (XENE) shares dropped 16% in after-hours trading after pausing enrollment in psychiatry trials due to neuropsychiatric adverse events. The pause is precautionary, and ongoing epilepsy studies are unaffected. The company filed an NDA for azetukalner in focal seizures, citing positive trial data. Topline data for MDD study expected in Q1 2027.

investing.com2 min